Thresholds for DNA-reactive (genotoxic) organic carcinogens

Journal of Toxicologic Pathology

Volumn 18, Issue 2, 2005, Pages 69-77

  Williams, Gary M ^a   Iatropoulos, Michael J ^a   Jeffrey, Alan M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

2 acetylaminofluorene; Carcinogens; DNA adducts; DNA damage; Neoplasms

Indexed keywords

EID: 24644470031     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.18.69     Document Type: Review

References (88)

1. Mantel N. The concept of threshold in carcinogenesis. Clin Pharm Ther. 4: 104-109. 1963.
2. Brown CC. Mathematical aspects of dose-response studies in carcinogenesis - the concept of thresholds. Oncology. 33: 62-65. 1976.
3. Gaylord DW. The question of the existence of thresholds: extrapolation from high to low dose. In: Mechanisms of Toxicity and Chemical Carcinogenesis and Mutagenesis. Flamm G and Lorentzen R (eds.). Princeton Sci. Pub. Co., Inc, Princeton. Vol. 12, 249-260. 1985.
4. Slob W. Thresholds in toxicology and risk assessment. Int J Toxicol. 18: 259-268. 1999.
5. Waddell WJ. Thresholds in chemical carcinogenesis: what are animal experiments telling us? Toxicol Pathol. 31: 260-262. 2003.
6. Haseman JK. An alternative perspective: a critical evaluation of the Waddell threshold extrapolation model in chemical carcinogenesis. Toxicol Pathol. 31: 468-470. 2003.
7. Williams GM. DNA reactive and epigenetic carcinogens. Exper Tox Path. 44: 457-464. 1992.
8. Williams GM, Karbe E, Fenner-Crisp P, Iatropoulos MJ, and Weisburger JH. Risk assessment of carcinogens in food with special consideration of non-genotoxic carcinogens: scientific arguments for use of risk assessment and for changing the Delaney Clause specifically. Exp Toxicol Pathol. 48: 209-215. 1996.
9. Kirsch-Volders M, Aardema M, and Elhajouji A. Concepts of threshold in mutagenesis and carcinogenesis. Mutat Res. 464: 3-11. 2000.
10. Lijinsky W, Kovatch RM, Riggs CW, and Walters PT. Dose-response study with N-nitrosomorpholine in drinking water of F-344 rats. Cancer Res. 48: 2089-2095. 1988.
11. Peto R, Gray R, Brantom P, and Grasso P. Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study. Cancer Res. 51: 6415-6451. 1991.
12. Peto R, Gray R, Brantom P, and Grasso P. Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine. Cancer Res. 51: 6452-6469. 1991.
13. Farmer JH, Kodell RL, Greenman DL, and Shaw GW. Dose and time responses models for the incidence of bladder and liver neoplasms in mice fed 2-acetylaminofluorene continuously. J Environ Pathol Toxicol. 3: 55-68. 1980.
14. Hino O and Kitagawa T. Existence of a practical threshold dose for the hepatocarcinogen 3'-methyl-4-(dimethylamino) azobenzene in rat liver. Gann. 72: 637-638. 1981.
15. Maekawa A, Onodera H, Matsushima Y, Nagaoka T, Todate A, Shibutani M, Kodama Y, and Hayashi Y. Dose-response carcinogenicity in rats on low-dose levels of N-ethyl-N-nitrosourethane. Jpn J Cancer Res. 80: 632-636. 1989.
16. Williams GM, Iatropoulos MJ, Wang CX, Jeffrey AM, Thompson S, Pitmann B, Palasch M, and Gebhardt R. Non-linearities in 2-acetylaminofluorene exposure-responses for genotoxic and epigenetic effects leading to initiation of carcinogenesis in rat liver. Toxicol Sci. 45: 152-161. 1998.
17. Fukushima S. Low-dose carcinogenicity of a heterocyclic amine, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline: relevance to risk assessment. Cancer Lett. 143: 157-159. 1999.
18. Williams GM, Iatropoulos MJ, Jeffrey AM, Luo FQ, Wang CX, Thompson S, and Pittman B. Diethylnitrosamine exposure-responses for DNA ethylation, hepatocellular proliferation and initiation of carcinogenesis in the rat liver display non-linearities and thresholds. Arch Toxicol. 73: 394-402. 1999.
19. Fukushima S, Wanibuchi H, Morimura K, Wei M, Nakae D, Konishi Y, Tsuda H, Uehara N, Imaida K, Shirai T, Tatematsu M, Tsukamoto T, Hirose M, Furukawa F, Wakabayashi K, and Totsuka Y. Lack of a dose-response relationship for carcinogenicity in the rat liver with low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline or N-nitrosodiethylamine. Jpn J Cancer Res. 93: 1076-1082. 2002.
20. Hengstler JG, Bogdanffy MS, Bolt HM, and Oesch F. Challenging dogma: thresholds for genotoxic carcinogens? The case of vinyl acetate. Annu Rev Pharmacol Toxicol. 43: 485-520. 2003.
21. Tsuda H, Fukushima S, Wanibuchi H, Morimura K, Nakae D, Imaida K, Tatematsu M, Hirose M, Wakabayashi K, and Moore MA. Value of GST-P positive preneoplastic hepatic foci in dose-response studies of hepatocarcinogenesis: evidence for practical thresholds with both genotoxic and nongenotoxic carcinogens. A review of recent work. Toxicol Pathol. 31: 80-86. 2003.
22. Borst P, Evers R, Kool M, and Wijnholds J. The multidrug resistance protein family. Biochim Biophys Acta. 1461: 347-357. 1999.
23. Williams GM and Weisburger JH. Chemical Carcinogenesis. In: Toxicology. Klaassen CD, Amdur MO, and Doull J (eds.), McGraw-Hill, New York. 127-200, 1991.
24. Swenberg JA, La DK, Scheller NA, and Wu KY. Dose-response relationships for carcinogens. Toxicol Lett. 82-83: 751-756. 1995.
25. Ehrenberg L, Hiesche KD, Osterman-Golkar S, and Wenneberg I. Evaluation of genetic risks of alkylating agents: tissue doses in the mouse from air contaminated with ethylene oxide. Mutat Res. 24: 83-103. 1974.
26. Hemminki K, Autrup H, and Haugen A. DNA and protein adducts. Toxicology. 101: 41-53. 1995.
27. Lewis DF, Ioannides C, and Parke DV. Cytochromes P450 and species differences in xenobiotic metabolism and activation of carcinogen. Environ Health Perspect. 106: 633-641. 1998.
28. Sheng J, Guo J, Hua Z, Caggana M, and Ding X. Characterization of human CYP2G genes: widespread loss-of-function mutations and genetic polymorphism. Pharmacogenetics, 10: 667-678. 2000.
29. Garner RC, Lightfoot TJ, Cupid BC, Russell D, Coxhead JM, Kutschera W, Priller A, Rom W, Steier P, Alexander DJ, Leveson SH, Dingley KH, Mauthe RJ, and Turteltaub KW. Comparative biotransformation studies of MeIQx and PhIP in animal models and humans. Cancer Lett. 143: 161-165. 1999.
30. Guengerich FP, Parikh A, Turesky RJ, and Josephy PD. Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype. Mutat Res. 428: 115-124. 1999.
31. Williams GM, Reiss B, and Weisburger JH. A comparison of the animal and human carcinogenicity of several environmental, occupational and therapeutic chemicals. In: Mechanisms and Toxicology of Chemical Carcinogens and Mutagens. Flamm G and Lorentzen R (eds.). Princeton Scientific Publishers. Princeton, NJ. Vol. IX, 207-248, 1985.
32. Vogelstein B and Kinzler KW. The multistep nature of cancer. Trends Genet. 9: 138-141. 1993.
33. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 400: 464-468. 1999.
34. Bos JL. RAS oncogenes in human cancer: a review. Cancer Res. 49: 4682-4689. 1989.
35. Root M, Lange T, and Campbell TC. Dissimilarity in aflatoxin dose-response relationships between DNA adduct formation and development of preneoplastic foci in rat liver. Chem Biol Interact. 106: 213-227. 1997.
36. 6-methylguanine from deoxyribonucleic acid in rat liver and kidney after small doses of dimethylnitrosamine. Biochem J. 173: 739-748. 1978.
37. 32P-postlabeling: relationships to cancer and aging. Exp Gerontol. 27: 533-549. 1992.
38. Randerath K, Li D, Moorthy B, and Randerath E. I-compounds - endogenous DNA markers of nutritional status, ageing, tumour promotion and carcinogenesis. IARC Sci Publ. 157-165, 1993.
39. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 21: 361-370. 2000.
40. Povey AC. DNA adducts: endogenous and induced. Toxicol Pathol. 28: 405-414. 2000.
41. Nestmann ER, Bryant DW, and Carr CJ. Toxicological significance of DNA adducts: summary of discussion with an expert panel. [Fennell, T.T., Gallagher, J.E., Gorelick, N.J., Swenberg, J.A., Williams, G.M.]. Reg Toxicol Pharmacol. 24: 9-18. 1996.
42. 6- methyldeoxyguanosine and enhanced mutagenesis in rat-liver epithelial cells. Mutat Res. 230: 219-226. 1990.
43. Philip PA, Souliotis VL, Harris AL, Salisbury A, Tates AD, Mitchell K, van Delft JH, Ganesan TS, and Kyrtopoulos SA. Methyl DNA adducts, DNA repair, and hypoxanthineguanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clin Cancer Res. 2:303-310. 1996.
44. Papanikolaou A, Shank RC, Delker DA, Povey A, Cooper DP, and Rosenberg DW. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol Appl Pharmacol. 150: 196-203. 1998.
45. Hilpert D and Neumann HG. Accumulation and elimination of macromolecular lesions in susceptible and nonsusceptible rat tissues after repeated administration of trans-4-acetylaminostilbene. Chem Biol Interact. 54: 85-95. 1985.
46. Jeffrey AM, Luo FQ, Amin S, Krzeminski J, Zech K, and Williams GM. Lack of DNA binding in the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylaniline. Drug Chem Toxicol. 25: 93-107. 2002.
47. Christmann M, Tomicic MT, Roos WP, and Kaina B. Mechanisms of human DNA repair: an update. Toxicology. 193:3-34. 2003.
48. Maslansky CJ and Williams GM. Ultraviolet light-induced DNA repair synthesis in hepatocytes from species of differing longevities. Mech Ageing Dev. 29: 191-203. 1985.
49. Lindahl T. Keynote: past, present, and future aspects of base excision repair. Prog Nucleic Acid Res Mol Biol. 68: xvii-xxxx. 2001.
50. 6-alkylguanine by alkyltransferases. Mutat Res. 462: 83-100. 2000.
51. Hanawalt PC, Ford JM, and Lloyd DR. Functional characterization of global genomic DNA repair and its implications for cancer. Mutat Res. 544: 107-114. 2003.
52. Tong C, Fazio M, and Williams GM. Cell cycle-specific mutagenesis at the hypoxanthine phosphoribosyltransferase locus in adult rat liver epithelial cells. Proc Natl Acad Sci USA. 77: 7377-7379. 1980.
53. Rabes HM, Kerler R, and Wilhelm R. DNA alkylation and tumor induction in regenerating rat liver after cell cycle-related continuous N-nitrosodimethylamine infusion. J Natl Cancer Inst. 70: 193-198. 1983.
54. Hirabayashi Y, Yoshida K, Aizawa S, Kodama Y, Kanno J, Kurokawa Y, Yoshimura I, and Inoue T. Evaluation of nonthreshold leukemogenic response to methyl nitrosourea in p53-deficient C3H/He mice. Toxicol Appl Pharmacol. 190:251-261. 2003.
55. Hart RW and Setlow RB. Correlation between deoxyribonucleic acid excision-repair and life-span in a number of mammalian species. Proc Natl Acad Sci USA. 71: 2169-2173. 1974.
56. Cortopassi GA and Wang E. There is substantial agreement among interspecies estimates of DNA repair activity. Mech Ageing Dev. 91: 211-218. 1996
57. Umemura T, Tokumo K, Gebhardt R, Poirier M, and Williams GM. Dose-response effects of 2-acetylaminofluorene on DNA damage, cytotoxicity, cell proliferation and neoplastic conversion in rat liver. Cancer Lett. 73: 1-10. 1993.
58. Poirier MC, Santella RM, and Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis. 21: 353-359. 2000.
59. Mah MC, Boldt J, Culp SJ, Maher M, and McCormick JJ. Replication of acetylaminofluorene-adducted plasmids in human cells: spectrum of base substitutions and evidence of excision repair. Proc Natl Acad Sci USA. 88: 10193-10197. 1991.
60. Lloyd DR and Hanawalt PC. p53-dependent global genomic repair of benzo[a]pyrene-7,8-diol-9,10-epoxide adducts in human cells. Cancer Res. 60: 517-521. 2000.
61. Clapper ML. Genetic polymorphism and cancer risk. Curr Oncol Rep. 2: 251-256. 2000.
62. Goode EL, Ulrich CM, and Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 11: 1513-1530. 2002.
63. 3H-ethyl metanesulfonate. Mutat Res. 24: 317-333. 1974.
64. Russell WL, Hunsicker PR, Raymer GD, Steele MH, Stelzner KF, and Thompson HM. Dose - response curve for ethylnitrosourea-induced specific-locus mutations in mouse spermatogonia. Proc Natl Acad Sci USA. 79: 3589-3591. 1982.
65. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 362: 709-715. 1993.
66. Shuker DE. The enemy at the gates? DNA adducts as biomarkers of exposure to exogenous and endogenous genotoxic agents. Toxicol Lett. 134: 51-56. 2002.
67. Chernozemski IN and Warwick GP. Liver regeneration and induction of hepatomas in B6AF mice by urethan. Cancer Res. 30: 2685-2690. 1970.
68. Tanaka T, Mori H, Hirota N, Furuya K, and Williams GM. Effect of DNA synthesis on induction of preneoplastic and neoplastic lesions in rat liver by a single dose of methylazoxymethanol acetate. Chem Biol Interact. 58: 13-27. 1986.
69. 1-induced enzyme altered hepatic foci in rats and hamsters. Carcinogenesis. 17: 2495-2499. 1996.
70. Hainaut P and Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 77: 81-137, 2000.
71. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, and Thornton JM. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 19: 149-164. 2002.
72. Greenblatt MS, Beaudet JG, Gamp JR, Godin KS, Trombley L, Koh J, and Bond JP. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene. 22: 1150-1163. 2003.
73. Parry JM, Jenkins GJ, Haddad F, Bourner R, and Parry EM. In vitro and in vivo extrapolations of genotoxin exposures: consideration of factors which influence dose-response thresholds. Mutat Res. 464: 53-63. 2000.
74. Knudson AG. Hereditary predisposition to cancer. Ann N Y Acad Sci. 833: 58-67. 1997.
75. Sugimura T, Terada M, Yokota J, Hirohashi S, and Wakabayashi K. Multiple genetic alterations in human carcinogenesis. Environ Health Perspect. 98: 5-12. 1992.
76. Zeise L, Wilson R, and Crouch EA. Dose-response relationships for carcinogens: a review. Environ Health Perspect. 73: 259-306. 1987.
77. Iatropoulos MJ and Williams GM. The function and pathology of brown adipose tissue in animals and humans. J Toxicol Pathol. 17: 147-153. 2004.
78. Williams GM and Watanabe K. Quantitative kinetics of development of N-2-fluorenylacetamide-induced, altered (hyperplastic) hepatocellular foci resistant to iron accumulation and of their reversion or persistence following removal of carcinogen. J Natl Cancer Inst. 61: 113-121. 1978.
79. Williams GM, Iatropoulos MJ, and Jeffrey AM. Mechanistic basis for nonlinearities and thresholds in rat liver carcinogenesis by the DNA-reactive carcinogens 2-acetylaminofluorene and diethylnitrosamine. Toxicol Pathol. 28: 388-395. 2000.
80. Williams GM, Iatropoulos M, and Jeffrey AM. Thresholds for the effects of 2-acetylaminofluorene in rat liver. Toxicol Pathol. 32 (suppl. 2): 246-252. 2004.
81. Enzmann H, Zerban H, Kopp-Schneider A, Loser E, and Bannach P. Effects of low doses of N-nitrosomorpholine on the development of early stages of hepatocarcinogenesis. Carcinogenesis. 16: 1513-1518. 1995.
82. Williams GM. Mechanisms of chemical carcinogenesis and application to human cancer risk assessment. Toxicology. 166: 3-10. 2001.
83. Williams GM. Interactive carcinogenesis in the liver. In: Falk Symposium: Liver Cell Carcinoma. Bannasch P, Keppler D, and Weber G (eds.). Academic Press, Boston. Vol. 51, 197-216, 1989.
84. Williams GM. Food-borne carcinogens. Prog Clin Biol Res. 206:73-81. 1986.
85. International Agency for Research on Cancer. editors. Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC, Lyons. 1993.
86. Koivusalo M and Vartiainen T. Drinking water chlorination by-products and cancer. Rev Environ Health. 12: 81-90. 1997.
87. Weisburger JH and Williams GM. Types and amounts of carcinogens as potential human cancer hazards. Cell Biol Toxicol. 5: 377-391. 1989.
88. Whysner J and Williams GM. International Cancer Risk Assessmnet: the impact of biologic mechanisms. Reg Toxicol Pharmacol. 15: 41-50. 1992.